SK Bioscience Co (XKRX:302440) Debt-to-EBITDA : 0.40 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is SK Bioscience Co Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

SK Bioscience Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₩8,137 Mil. SK Bioscience Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₩12,436 Mil. SK Bioscience Co's annualized EBITDA for the quarter that ended in Dec. 2023 was ₩51,851 Mil. SK Bioscience Co's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was 0.40.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for SK Bioscience Co's Debt-to-EBITDA or its related term are showing as below:

XKRX:302440' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.22 Med: 1.38 Max: 6.54
Current: 0.47

During the past 6 years, the highest Debt-to-EBITDA Ratio of SK Bioscience Co was 6.54. The lowest was 0.22. And the median was 1.38.

XKRX:302440's Debt-to-EBITDA is ranked better than
69.06% of 278 companies
in the Biotechnology industry
Industry Median: 1.355 vs XKRX:302440: 0.47

SK Bioscience Co Debt-to-EBITDA Historical Data

The historical data trend for SK Bioscience Co's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SK Bioscience Co Debt-to-EBITDA Chart

SK Bioscience Co Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-EBITDA

Get a 7-Day Free Trial

3.36

2.10

0.22

0.66

0.47

SK Bioscience Co Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-EBITDA	Get a 7-Day Free Trial															0.73	-1.00	-0.33	0.09	0.40

Competitive Comparison of SK Bioscience Co's Debt-to-EBITDA

For the Biotechnology subindustry, SK Bioscience Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

SK Bioscience Co's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SK Bioscience Co's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where SK Bioscience Co's Debt-to-EBITDA falls into.

SK Bioscience Co Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

SK Bioscience Co's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(8137.402	+	12436.126)	/	43490.069
	=	0.47

SK Bioscience Co's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(8137.402	+	12436.126)	/	51850.88
	=	0.40

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.

SK Bioscience Co (XKRX:302440) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

SK Bioscience Co Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of SK Bioscience Co's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

SK Bioscience Co (XKRX:302440) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SK Bioscience Co Ltd (XKRX:302440) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

N/A

Address

310, Pangyo-ro, Bundang-gu, Gyeonggi-do, Seongnam-si, KOR, 13494

Website

https://www.skbioscience.co.kr

SK Bioscience Co Ltd is a South Korean pharmaceutical company. It is engaged in the manufacturing and developing of vaccine. The company has registered SKYCellflu prefilled syringe (PFS), the first cell culture influenza vaccine in Korea, followed by the licensure of SKYCellflu Quadrivalent prefilled syringe and 13-valent Pneumococcal Conjugate Vaccine. Further it has several other vaccines under development and clinical trials including recombinant rotavirus vaccine. In addition, the development of new typhoid conjugate vaccine and innovative pneumococcal vaccine is ongoing in collaboration with external partners.

SK Bioscience Co (XKRX:302440) Headlines

No Headlines